Portolan Capital Management LLC Has $72.70 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Portolan Capital Management LLC grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 812,630 shares of the medical equipment provider's stock after purchasing an additional 141,749 shares during the quarter. Lantheus accounts for 4.9% of Portolan Capital Management LLC's investment portfolio, making the stock its biggest position. Portolan Capital Management LLC owned 1.17% of Lantheus worth $72,698,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus during the 3rd quarter valued at approximately $25,000. Kestra Investment Management LLC bought a new position in Lantheus during the 4th quarter worth $27,000. Summit Securities Group LLC acquired a new stake in shares of Lantheus in the 4th quarter worth about $37,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its stake in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after acquiring an additional 280 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock valued at $6,016,046 over the last quarter. Company insiders own 1.50% of the company's stock.

Lantheus Stock Performance

LNTH traded up $0.80 during trading on Friday, reaching $101.32. The company had a trading volume of 430,521 shares, compared to its average volume of 955,268. Lantheus Holdings, Inc. has a 12-month low of $61.47 and a 12-month high of $126.89. The company has a market cap of $6.94 billion, a price-to-earnings ratio of 16.86 and a beta of 0.20. The firm's 50-day simple moving average is $95.00 and its 200 day simple moving average is $95.55.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

LNTH has been the subject of several research analyst reports. Truist Financial upped their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Finally, JMP Securities reiterated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.